Clinuvel Pharmaceuticals Ltd
ASX:CUV
Clinuvel Pharmaceuticals Ltd
PP&E Net
Clinuvel Pharmaceuticals Ltd
PP&E Net Peer Comparison
Competitive PP&E Net Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
PP&E Net
AU$7.9m
|
CAGR 3-Years
39%
|
CAGR 5-Years
89%
|
CAGR 10-Years
51%
|
|
Immutep Ltd
ASX:IMM
|
PP&E Net
AU$795.5k
|
CAGR 3-Years
34%
|
CAGR 5-Years
84%
|
CAGR 10-Years
0%
|
|
Mesoblast Ltd
ASX:MSB
|
PP&E Net
$5.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
PP&E Net
$9.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
PP&E Net
AU$30.5m
|
CAGR 3-Years
85%
|
CAGR 5-Years
167%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
PP&E Net
AU$1.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
48%
|
CAGR 10-Years
15%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's PP&E Net?
PP&E Net
7.9m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's PP&E Net amounts to 7.9m AUD.
What is Clinuvel Pharmaceuticals Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
51%
Over the last year, the PP&E Net growth was 212%. The average annual PP&E Net growth rates for Clinuvel Pharmaceuticals Ltd have been 39% over the past three years , 89% over the past five years , and 51% over the past ten years .